国产创新药可从四方面入手筑牢长红根基

Core Viewpoint - Since December, several domestic innovative pharmaceutical companies have announced the activation of cooperation agreements with overseas pharmaceutical giants to jointly promote the global development and commercialization of domestic innovative drugs. Data indicates that by the third quarter of 2025, Chinese pharmaceutical companies will have completed 103 outbound licensing transactions, totaling $92.03 billion, with the total for the year expected to exceed $100 billion. This reflects the market's recognition of Chinese innovative drugs. However, to transition from "one-time licensing frenzy" to "sustained value creation," domestic innovative pharmaceutical companies must overcome development bottlenecks by focusing on four key areas [1]. Group 1 - Leverage policy dividends to promote the rise of domestic innovative drugs. The approval cycle for innovative drugs in China has significantly shortened, with many included in medical insurance and a higher negotiation success rate than the industry average. Companies should utilize policy benefits to drive innovation breakthroughs, focusing on urgent clinical needs in areas like oncology and rare diseases, and establish cross-border innovative drug trading platforms to facilitate "going global" [2]. Group 2 - Emphasize talent as a key support for the development of innovative drugs. While China has a large pool of biopharmaceutical talent, there is a shortage of high-end talent. To overcome this bottleneck, domestic innovative pharmaceutical companies should build a collaborative system among industry, academia, and research, establish platform laboratories through school-enterprise cooperation, and cultivate interdisciplinary talents who understand both biology and medicine. Additionally, implementing mechanisms like technology equity and stock incentives can enhance the retention of core talent [3]. Group 3 - Utilize artificial intelligence technology to reduce costs and increase efficiency in innovative drug development. The rapid advancement of AI technology is enhancing its application in drug development, shortening average R&D cycles and helping to reduce costs. Domestic innovative pharmaceutical companies should seize AI opportunities by creating platforms that integrate high-throughput laboratories with AI algorithms, establishing a closed loop of "data-algorithm-experiment," and promoting AI's penetration from target discovery to clinical optimization. Furthermore, companies should actively participate in formulating international AI pharmaceutical standards and develop AI-assisted systems tailored to Chinese clinical characteristics [4]. Group 4 - Strengthen industry chain collaboration to build a solid foundation for risk resistance. Domestic innovative pharmaceutical companies need to establish a collaborative system across all stages, from R&D to production, clinical trials, and sales. They should cultivate the supply capacity of high-end excipients and pharmaceutical equipment to enhance industry resilience and international influence. In the current market enthusiasm, companies must recognize that the surge in licensing transactions is merely the starting point for "going global," and continuous innovation and overcoming technical barriers are essential to becoming a lasting force in the global pharmaceutical market [5].